[KEYNOTE-426 : Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma].

[KEYNOTE-426 : Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma]. Urologe A. 2020 May 26;: Authors: Bedke J, Stühler V PMID: 32458147 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32458147?dopt=Abstract

Source: Der Urologe. Ausg. A - May 25, 2020 Category: Urology & Nephrology Authors: Bedke J, Stühler V Tags: Urologe A Source Type: research

More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology